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ABSTRACT
Cancer metastasis is a multistep process, which results in cancer cells disseminating to other organs. The crucial 
metastasis step involves cancer invasion which occurs via actin-protrusion by invasive malignant cells, termed as 
invadopodia. In solid tumours, invadopodia formation increases as a result of hypoxia which is found to be resis-
tant against chemotherapy and radiotherapy. Phytochemicals have been potentially identified as a prime source 
of effective conventional drugs for metastasis treatments, which target cancer cell invasion, particularly molecular 
components of the invadopodia formation. The Hypoxia-Inducible Factor-1α (HIF-1α) is an essential target in terms 
of treatment for hypoxic tumour, as well as helping to identify the mode of action for the drugs, particularly phy-
tochemical compounds. The aim of this review is to highlight the current development with regards to the ability 
of phytochemicals in targeting cancer metastasis, as well as   phytochemical compounds which are able to inhibit 
HIF-1α and invadopodia formation. The use of phytochemicals for targeting hypoxic cancer cells may open new 
prospects for reducing cancer metastasis. 
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INTRODUCTION
Cancer is one of the leading causes of death globally. 
In 2018, about 18.1 million patients were estimated to 
have been diagnosed with cancer across 185 countries 
(1). The majority of cancer mortality incidents were not 
caused by the primary tumour itself, but due to effects 
of cancer metastasis. Metastasis was revealed to account 
for 90% of mortalities (1,2). Metastasis is defined as 
a systemic disease, in which cancer cells have the 
ability to invade and migrate across other organs (3). 
Metastasis undergoes several stages, including invasion, 
angiogenesis, as well as migration. The most critical step 
in metastasis is cancer cell invasion through specific 
protrusion structures, these protrusions are termed 
as invadopodia (4). Invadopodia has been proven to 
play a fundamental function in the degradation of the 
extracellular matrix (ECM) (5). Invadopodia consists 
of a rich actin core which is surrounded by important 
recruit components which are essential for the invasion. 
The components include adhesion proteins, invasion 
proteins, cytoskeletal modulators, and signaling 
molecules (6).
Subsequently, invadopodia formation, ECM degradation, 
and invasiveness of the cancer cells gradually increase 
due to a series of events which occur in the solid 
tumor itself, which is termed as hypoxia (7). Hypoxia 
is a common tumour microenvironment phenomenon 
which exists across 90% of patients diagnosed with 
solid tumors (7). HIF-1α is a transcriptional factor which 
expresses in hypoxia. Interestingly, hypoxia enhances 
the ability of the solid tumour to become resistant 
toward chemotherapy and radiotherapy therapies. 
Because chemotherapeutic agents require cell activity 
in order to carry out its action. Radiotherapy on the 
other hand, needs oxygen as well to allow the radiation 
to effectively make small breaks in the DNA within the 
cells (8,9). Thus, any therapy which seeks to decrease the 
HIF-1α expression may be represented as a very useful 
complementary treatment for tumor hypoxia, as well as 
for invadopodia formation. Based on literature works, 
phytochemicals have been widely recognized as being 
able to target multiple signaling pathways across cancer 
cells, both directly and indirectly (10). Over than 5000 
specific phytochemical compounds have been known to 
decrease the threat of developing chronic diseases, such 
as diabetes, cancers and cardiovascular diseases (11). 
The number of the phytochemical compounds have 
increased tremendously over the last couple years due to 
numerous identification, isolation and characterization 
techniques (12,13). Therefore, the aim of this review 
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is to highlight the phytochemical compounds, which 
are able to target hypoxia, and invadopodia formation 
which lead to decrease metastasis.
ROLE OF INVADOPODIA FORMATION AND ITS 
MECHANISM OF ACTION IN METASTASIS
Cancer cell invasion is the primary step of metastasis 
(14). The invasion pervades via actin-foot protrusions, 
termed as invadopodia. Typically, it is formed in 
the ventral of the invasive cancer cells. Invadopodia 
is typically assayed by an ECM degradation assay 
which is composed of a gelatin coated coverslip in-
vitro. Invadopodia can be formed in several cancer 
cell lines, such as MDA-MB-231 breast cancer cells, 
A375 melanoma cells, RT25 bladder cancer cells, and 
HCT116 colon cancer cells which enable them to be 
widely used in invadopodia studies (15,16,17).
In order for cancer cells to metastasis successfully, 
cancer cells are required to move across ECM barriers 
into the blood flow stream.  ECM has been identified 
as a barrier which enables cell movement. Thus, 
invadopodia is required for penetration of these 
barriers (18,19). Studies have shown that invadopodia 
recruits various components and signalling to drive 
the degradation of ECM, for example actin filaments, 
integrins and metalloproteinases (MMPs), and signaling 
proteins, which regulate the actin cytoskeleton (20). 
Most importantly, invadopodia is only present in highly 
invasive carcinoma cells, and not all types of cancer 
cells are able to form invadopodia. However, many 
of these cell types can form protrusions, for example, 
endothelial cells, immune cells, dendritic cells and 
macrophages. These cells use protrusions for migration 
and/or phagocytosis, not for ECM degradation. This 
characteristic makes the carcinoma cells different from 
normal cells (21,22).
The main function of invadopodia is to degrade the 
ECM in order to facilitate migration. ECM is defined as 
a collection of materials such as periostin, hyaluronan, 
proteoglycans, minerals and fibrous proteins collections 
which fill the spaces between cells and surrounding 
tissues (4). Moreover, to complete the invadopodia 
function, it has to go through several initiation stages, 
including adhesion of cancer cells to ECM, degradation 
of ECM molecules, expansion, and footing of invasive 
cell into ECM. Finally, the cell body moves through the 
consequential space within the ECM, and migrates into 
the blood flow (23,24). 
The mechanical initiation of invadopodia could be 
divided into four steps. First, during the early initiation 
phase, the invadopodia precursors are non-degradable 
(75). During the second phase, these precursors are 
motile, and move around the ventral membrane. The 
third and fourth steps involve the maturation of the 
invadopodia. In the third step, the activation of the 
actin polymerization, stimulation by the NHE-1 cofilin 
pathway, and the actin polymerization, continues to 
drive the invadopodia elongation. In the fourth step, 
microtubules and intermediate filaments are recruited 
to degrade the ECM using metalloproteinase proteins 
(25). Thus, targeting invadopodia helps reduce cancer 
metastasis (26). 
INVADOPODIA FORMATION AS A POTENTIAL 
PROGNOSTIC MARKER FOR METASTASIS 
Highly invasive tumour cells have the ability to 
invade the surrounding tissues through invadopodia 
via intravasation and extravasation. Intravasation and 
extravasation are one of several metastasis events which 
initiate the release of cancer cells through ECM, into 
and out of lymphatic and blood vessels. Therefore, 
metastatic cascade is highly associated with invadopodia 
formation (4,101). Primary tumour cells obtained from 
cases which displayed malignant tumours have been 
shown the ability to form invadopodia (27). Invadopodia 
markers such as actin, cortactin and MMPs proteins 
were present in the primary cancer cells when they were 
cultured via in-vitro on the gelatine coated coverslip by 
determining the gelatine degradation (27). Thus, in-vitro 
invadopodia formation and ECM degradation assays can 
be used together as a prognostic indicator for invasive 
tumours in patient’s biopsies (28). In this literature 
work, we propose the use of invadopodia formation as 
a tool for predicting the response of cancer cell lines for 
phytotherapy or chemotherapy, as well as to investigate 
of the cancer invasiveness in malignant cancer patients 
via in-vitro.
MECHANISMS OF HYPOXIA AND ITS ROLE IN 
METASTASIS
Hypoxia occurs during the early phase of cancer 
metastasis. It promotes invasion and angiogenesis (29). 
The level of oxygen in the tumour tissue should be less 
than 5 - 10 mmHg for it to be considered as hypoxia 
in human tissues. However, the level of oxygen is 
typically low due to the exponential cellular growth and 
inadequate vascular supply (30). Thus, the metabolic 
activity of cancer cells in hypoxia rely on glycolysis to 
generate energy (31). This helps hypoxic cancer cells 
to increase their invasiveness. Studies have found that 
hypoxia exist in several cancer types, including breast, 
brain and cervical cancers (32). Previous studies have 
supported the fact that the molecular key in hypoxia is 
HIF-1α, which plays a fundamental role in interceding 
the survival of cancer cells (33). On the other hand, in 
normoxia, HIF-1α is typically hydroxylated by prolyl 
hydroxylases (PHDs) that demand O2 molecules to 
function as a substrate. The Von Hippel-Lindau (VHL) 
is part of the E3 ubiquitin ligase complex which 
helps to regulate the proteasome pathway to degrade 
HIF-1α (34). Therefore, HIF-1α is highly expressive 
under hypoxic conditions since PHDs and VHLs are 
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inhibited (Figure 1). Thereafter, HIF-1α translocate to 
a nucleus to alter major genes which regulate survival, 
metastasis, angiogenesis and invasion (35,36). Data 
from various studies have shown that hypoxia is 
resistant to radiotherapy and chemotherapy. Some 
of the chemotherapy drugs known to be resistant to 
hypoxia include sorafenib, adriamycin, gemcitabine, 
5-fluorouracil, cisplatin, and 6-thioguanine (37). These 
drugs were tested in cell lines, which included HepG2, 
BEL-7402, and SMMC-7721 (37). At present, hypoxia is 
recognized as a highly influential factor in terms of solid 
tumor treatment (38). Moreover, hypoxia increases the 
aggressiveness of cancer cells due to the instability of 
genes which regulate HIF-1α and increase the glycolysis 
pathways, such as GLUT1 and GLUT3 (39). Thus, the 
synthesis of drugs which is non-resistant under hypoxic 
conditions may give an opportunity for the treatment of 
hypoxic tumors (40,41).
diseases such as bacterial infections and inflammation 
(42). Numerous studies have proposed the use of 
phytochemicals as complementary drugs to treat several 
types of cancer (43). In addition, chemoprevention 
through the use of phytochemicals is much more 
cost efficient, safer and non-toxic when compared to 
chemotherapy (43). Furthermore, pharmacological 
mechanism studies on natural products have shown that 
phytochemicals do not only show beneficial bioactivities 
for treatment of inflammation and antioxidation, but 
also target multiple cancer-related processes (44). For 
example, cancer cell invasion and proliferation in 
MDA-MB231, MCF-7 and BT-483  breast cancer cells 
can be suppressed using curcumin, a phytochemical 
compound which is extracted from turmeric. It targets 
NF-kB and MMP-1 (45). In addition, when H460 and 
A549 lung cancer cells were treated using the same 
compound, apoptosis was increased, and metastasis 
progression which targeted ROS, MMP9, Nox2 and 
ATF2 was decreased (46,47). On the other hand, 
resveratrol which is a part of the polyphenol compound 
group, successfully suppressed ROS-induced migration 
and proliferation via inhibition of NFkB, ERK and 
E-cadherin in PANC1 and BxPC3 pancreatic cancer 
cells (48). In addition, resveratrol inhibited the survival 
of cancer cells by targeting angiogenesis in breast 
cancer cells (49). Several examples of phytochemicals 
which have displayed a molecular effect against a 
variety of cancer types  are shown in Table I. Thus, 
phytochemicals are a promising alternative in cancer 
therapy measures. Several phytochemicals have low 
solubility and stability, which limit their application for 
such treatment. Therefore, recent studies have sought 
the use of nanoparticles from phytochemicals in order 
to increase the solubility and stability of the compounds, 
besides enhancing their cellular uptake in in-vitro and 
in-vivo modules (43,49,50).
THE PROSPECTIVE APPROACH TO TARGET 
INVADOPODIA IN HYPOXIC CELLS VIA 
PHYTOTHERAPY
During cancer invasion, invadopodia formation increased 
with HIF-1α expression in hypoxia. Several reports have 
indicated that HIF-1α expressions increased the number 
of cells formed with invadopodia, which was treated 
with dimethyl-oxaloylglycine (DMOG) (7). DMOG 
is a chemical inducer which is widely used to mimic 
hypoxia. In addition, DMOG helped to quickly stabilize 
HIF-1α levels. It not only exhibited invadopodia-forming 
activities, but also increased the gelatine degradation 
in MDA-MB-231 cells by increasing the protrusion 
numbers in each cell (Figure 2) (7,51). Many studies 
have demonstrated that the molecular components of 
invadopodia, such as metalloproteinases (MMPs) in 
membrane type 1 matrix metalloproteinase (MT1-MMP), 
and matrix metalloproteinase-2 (MMP2) will increase 
upon exposure to hypoxia in MDA-MB231 breast 
cancer cells (52,53). Recent studies have shown that 
Figure 1:  Mechanism of HIF-1α in the hypoxic tumor cells. HIF-1α 
enables tumor progression after translocation into the nucleus in hy-
poxic condition by inducing alternative metabolic pathways within 
cancer cells. The possible therapeutic intervention goal is hydroxyla-
tion that leads to HIF-1α degradation binding.
Possibility of phytochemical use for cancer prevention 
Recently, Phytochemicals have been used to prevent 
cancer formation or development. Previous reports have 
exhibited that phytochemicals containing phenolic 
compounds, such as phenolic acids, flavonoids, 
tannins, curcuminoids, coumarins and quinones have 
the capability to prevent cancer progression. This can 
be achieved through inhibition of metastasis processes, 
such as the proliferation of cell regulators, including 
Erk1/2 and angiogenic factors, including VEGF, FGFR1 
and MIC-1. Invasion and migration regulators include 
MMPs, β-PIX, F-actin, Cortactin, Arp2/3, and N-WASP 
(70,71). The antioxidant potential of the phytochemical 
compound is well-thought-out in the treatment and 
prevention of cancer (72). Previous reports have 
suggested that phenolic compounds directly affect the 
cell regulation cycle. The studies also concluded that 
regular utilization of natural foods which have suitable 
phenolics, may be useful for cancer prevention (73,74).
The potential role of phytochemicals in cancer therapy
Phytochemicals are a group of bioactive compounds 
that are metabolically formed and synthesized in 
plants. Recently, considerable attention has been drawn 
toward the roles of phytochemicals against hallmark 
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invadopodia formation is affected by the high passage 
number, suggesting that only low passage numbers 
should be used in order to get accurate results (54). Recent 
studies have shown that a compound known as 2,6-bis-
(4-hydroxy-3-methoxybenzylidine) cyclohexanone, a 
phytochemical derived from turmeric, helps to reduce 
invadopodia formation, and significantly lowers the 
molecular components of invadopodia, such as MT1-
MMP, the Rho guanine nucleotide exchange factor 
7 known as β-PIX, and MMP-9 in MDA-MB231 cells 
under normoxic conditions (55). Further phytochemical 
compounds studied the molecular components of 
invadopodia, suggested that phytochemicals have the 
ability to decrease cancer progression (76). Therefore, 
based on the presented information, by targeting 
invadopodia formation, this has helped to open an 
interesting area of research in hypoxic solid tumors 
using phytochemicals as a synergistic treatment.
INFLUENCE OF PHYTOCHEMICALS ON HIF-1α AND 
RELATED INVASION SIGNALING PATHWAYS
HIF-1α is a major molecular factor in hypoxia, which 
regulates the expression of genes involved in many 
cancer biology properties, including angiogenesis, 
proliferation, invasion and metabolism (41,56, 
57,58). Literally, little information was found, which 
involves studying the effects of natural compounds on 
invadopodia formation under hypoxia. Some of studies 
have shown that neolamellarins extracted from marine 
sponge Dendrilla Nigra inhibit HIF-1α in T47D human 
breast cancer cells (59,60). Another study showed that 
apigenin, a phytochemical compound, belongs to the 
flavonoids group, which successfully inhibited HIF-
1α and vascular endothelial growth factors (VEGF) in 
PC3-M prostate carcinoma cells (61). VEGF regulated by 
HIF-1α in hypoxic condition, it induces angiogenesis in 
tumour hypoxia (61). Furthermore, an active compound 
used in traditional Chinese medicine called vitexin, was 
also found to have anti-cancer properties. Vitexin is an 
apigenin flavone glucoside, found in various medicinal 
plants and used as an antioxidant, anticancer and anti-
inflammatory agent (62). It has been shown to inhibit 
Figure 2: Illustrate cancer cells forming invadopodia in normoxia and hypoxia. The figure shows the number of invadopodia 
formation in hypoxia is higher than normoxia. This is largely due to the high expression of HIF- 1α in hypoxia that induces many 
signaling pathways involved in invadopodia.
Table I: Potential phytochemicals obtained from medicinal plants 
against various types of cancer
Name of the 
plant
Compound 
name
Study 
type
Molecular target Reference
Chrysan-
themum 
morifolium
Luteolin In-vitro Inhibited VEGF 
production and it’s 
receptor’s activity.
(102)
Rabdosia 
rubescens
Oridonin In-vitro Induced apoptosis, 
displayed an-
ti-proliferation and 
anti-angiogenesis 
properties across 
various cancer 
types.
(103)
Ligustrum 
lucidum, 
Sambucus 
chinensis
Ursolic acid In-vitro Activated the 
apoptosis via 
ROCK/PTEN in 
the LNCaP human 
prostate cancer 
cells.
(104)
Panax Gin-
seng
Ginsenoside 
Rh2
In-vitro & 
in-vivo
Inhibited cancer 
cell growth and 
survival.
(105)
Sinomenium 
acutum
Sinomenin In-vitro Suppressed cell 
proliferation and 
migration in breast 
cancer cells.
(106)
Coptidis Rhi-
zoma, Coptis 
japonica
Berberine In-vitro & 
in-vivo
Induced apoptosis 
via the AMPK-p53 
pathway in breast 
cancer cells.
(107)
Epimedium 
brrvicornum
Icariin In-vitro Decreased migra-
tion and viability 
of HCT116 colon 
cancer cells.
 (108)
Allium 
sativum
Allicin In-vitro Reduced cell via-
bility and prolifera-
tion across various 
cancer cells.
(109)
Tripterygium 
wilfodii
Celastrol In-vitro Displayed 
anti-angiogenic, 
anti-metastatic and 
inti-inflammatory 
characteristics 
across different 
cancer cells.
(110)
Trichosanthes 
kirilowii
Cucurbita-
cin D
In-vitro & 
in-vivo
Showed anti-can-
cer activities via 
inhibition of the 
expression of E6, 
Cycline D1, and 
CDk4. Also helped 
induce the protein 
levels of P21 and 
P27 in cervical 
cancer cells.
(111)
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HIF-1α expressions in PC12 aderenal medulla cells, a 
tumor adrenal gland of a rat (63). To date, curcumin 
is one of the most widely studied phytochemicals for 
treating hypoxic cells. Curcumin is a bright yellow 
pigment produced from the rhizome of the plant 
Curcuma longa L., which is widely employed in Asian 
traditional medicine for treating numerous illnesses 
such as diabetes, cough, inflammation and tumours 
(64,65,65). Previous studies have reported the use 
of curcumin in various kinds of cancer treatments, 
including colon, pancreatic, breast, and brain, by 
inhibition of cell invasion, migration and angiogenesis. 
The effects of curcumin on hypoxic tumour cells have 
been widely discussed. Curcumin significantly inhibits 
HIF-1α protein levels by inducing HepG2 hepatocellular 
carcinoma cells (66,67). Curcumin plays a vital function 
in suppressing hypoxia-induced invasion, migration 
and in-vitro proliferation by reducing Hedgehog 
signalling pathway in pancreatic cancer cells (68). 
Moreover, curcumin helped prevent hypoxia-stimulated 
angiogenesis in vascular epithelial cells by reducing 
HIF-1α and VEGF expressions (69). These studies have 
suggested that curcumin could be a possible candidate to 
target hypoxic tumour via inhibition of HIF-1α. We have 
organized several phytochemical compounds according 
to their effects on HIF-1α and invasion (invadopodia) 
related signaling pathways in Table II. Based on the 
information presented, further investigations are needed 
on new phytochemical compounds which are able 
to inhibit HIF-1α at the molecular level, in order to 
decrease the metastasis.
CONCLUSION
Hypoxic cancer cells pose a unique problem. It brings 
about an opportunity for the design of therapeutic 
approaches based on the biological and physiological 
treatment activities. By targeting HIF-1α, invadopodia 
and angiogenesis under hypoxic conditions could be 
an alternative for the treatment of solid tumour using 
phytochemical compounds. The molecular targets 
of hypoxia and invadopodia are mostly understood, 
but the specific treatment that inhibits these targets 
without harming the healthy cells still needs more 
investigation. Therefore, studies on the biological 
activities of phytochemicals which target hypoxia 
tumours, invadopodia and angiogenesis, may be 
added to the growing understanding of treatment with 
regards to phytochemicals in hypoxic tumour cells. In 
the future, the potential effects of phytochemicals on 
hypoxia tumours and invadopodia formation, as well as 
angiogenesis should be considered.
REFERENCES 
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, 
Torre LA, Jemal A. Global cancer statistics 2018: 
GLOBOCAN estimates of incidence and mortality 
worldwide for 36 cancers in 185 countries. CA: A 
Table II: Phytochemical compounds inhibit HIF-1α and related signal-
ing pathways of invadopodia formation.
Phytochemical 
compound
Effects on HIF-1α and cell invsion related signaling 
pathways
References
Luteolin Caused inhibition of invadopodia formation 
and reduced the phosphorylation of cortactin and Src 
in A431-III cells.
Inhibited hypoxia-induced VEGF and HIF-1α expres-
sions in the low micromolar range within NCI-H157 
cells.
(76)
(77)
Apigenin Inhibited motility and invasion of PC3-M prostate 
carcinoma cells by focal adhesion of kinase/Src  via 
signalling mechanisms.
Inhibited HIF-1α, GLUT-1 and VEGF mRNA protein 
expressions in pancreatic cancer cells under  hypoxic 
and normoxic conditions.
(78)
(79)
Vitexin Inhibited HIF-1α, collagen type III and VEGF in PC12 
cells.
(63)
Deguelin Blocked HIF-1α and angiogenesis in lung cancer cells.
Inhibited the essential invasion signals, including 
CD44, MMP2, MMP-9, Rac1 and Rock1 in the mRNA, 
as well as protein levels in A549 and H460 human lung 
cancer cell lines.
(80)
(81)
Quercetin Inhibited invadopodia formation and decrement in 
ECM A431-III cells. May potentially inhibit cancer 
metastasis via Akt/mTOR/c-Myc signalling pathways in 
A431-III cells.
Induced HIF-1α expressions in hypoxic and normoxic 
conditions in the human HepG2 hepatoma cells and 
activated the HIF-1α signalling pathways in human lens 
epithelial cells.
(76, 82)
(83, 84)
Curcumin Suppressed lung cancer cell line growth via in-vitro and 
in-vivo invasiveness through MMP2 and MMP-9.
Inhibited HIF-1α in many cell lines including Hep3B hepa-
toma cells, MCF-7 breast cancer cells, HT29 colon carcino-
ma, PC3 prostate carcinoma cells, Caki-
1
 renal carcinoma, 
H596 lung carcinoma, MDA-MB-231 breast cancer, 1A9 
human ovarian cells and xeno-grafted tumours.
(85)
(86, 87, 88)
Sodwanones Inhibited hypoxia-induced HIF-1 activation in T47D 
breast tumour cells.
Effects of Sodwanones on cancer invasiveness was not 
elucidated.
(89)
(90)
Baicalein Inhibited HIF-1α stability.
Suppressed adhesion, migration and invasion of MDA-
MB-231 breast cancer cells through down-regulated 
expressions of MMP-2 and MMP-9. 
(90)
(91)
Zerumbone Inhibited CXL12-induced invasion of breast cancer and 
pancreatic tumour cells.
Effects of Zerumbone on HIF-1α is not elucidated.
(92)
Silibinin Reduced HIF-1α expressions in PCa prostate cancer 
cells.
Inhibited the invasiveness of PC3 prostate cancer cells 
via integrin signalling.
(93)
(94)
Resveratrol Inhibited breast cancer cells invasion through inactivat-
ed Rho/YAP signalling axis and decreased the levels of 
MMP-2 and MMP-9 in human hepatocarcinoma cells.
Reduced HIF-1α and VEGF expressions in human 
tongue squamous carcinoma cells.
(95, 96 )
(97)
Anthocyanins Inhibited cancer invasion through inhibition of MMP-2 
expressions in a dose-dependent manner in Hela cervi-
cal cancer cells as well as A549 lung carcinoma cells.
Effects of Anthocyanins on HIF-1α is not elucidated in 
cancer related research works.
(98,99)
Cancer Journal for Clinicians. 2018 Nov;68(6):394-
424.
2.  Chaffer CL, Weinberg RA. A perspective on cancer 
cell metastasis. Science. 2011; 331(6024):1559-
64.
3. Weigelt B, Peterse JL, Van’t Veer LJ. Breast cancer 
metastasis: markers and models. Nature Reviews 
Mal J Med Health Sci 15(SP2): 71-80, July 201976
Malaysian Journal of Medicine and Health Sciences (eISSN 2636-9346)
Cancer. 2005; 5(8):591-602.
4. Paz H, Pathak N, Yang J. Invading one step at a 
time: the role of invadopodia in tumor metastasis. 
Oncogene. 2014; 33(33):4193-202.
5. Linder S. The matrix corroded: podosomes and 
invadopodia in extracellular matrix degradation. 
Trends in Cell Biology. 2007; 17(3):107-17.
6. Murphy DA, Courtneidge SA. The ‘ins’ and ‘outs’ 
of podosomes and invadopodia: characteristics, 
formation, and function. Nature Reviews Molecular 
Cell Biology. 2011; 12(7):413-26.
7. Hashim NF, Nicholas NS, Dart AE, Kiriakidis 
S, Paleolog E, Wells CM. Hypoxia-induced 
invadopodia formation: a role for β-PIX. Open 
Biology. 2013; 3(6): 120159.
8. Hockel M, Vaupel P. Tumour hypoxia: definitions 
and current clinical, biologic, and molecular 
aspects. Journal of the National Cancer Institute. 
2001; 93(4):266-76.
9. Shannon AM, Bouchier-Hayes DJ, Condron CM, 
Toomey D. Tumour hypoxia, chemotherapeutic 
resistance and hypoxia-related therapies. Cancer 
Treatment Reviews. 2003; 29(4):297-307.
10. Cheng YT, Yang CC, Shyur LF. Phytomedicine 
- Modulating oxidative stress and the tumor 
microenvironment for cancer therapy. 
Pharmacological Research. 2016; 114:128-43.
11. Liu RH. Whole grain phytochemicals and health. 
Journal of Cereal Science. 2007; 46(3):207-19.
12. Salehi B, Zucca P, Sharifi‐Rad M, Pezzani R, Rajabi 
S, Setzer WN et al., Phytotherapeutics in cancer 
invasion and metastasis. Phytotherapy Research. 
2018; 32(8):1425-1449.
13. Adorjan B, Buchbauer G. Biological properties 
of essential oils: an updated review. Flavour and 
Fragrance Journal. 2010; 25(6):407-26.
14. van Zijl F, Krupitza G, Mikulits W. Initial steps 
of metastasis: cell invasion and endothelial 
transmigration. Mutation Research/Reviews in 
Mutation Research. 2011; 728(1-2):23-34.
15. Zhang E, Zhang C, Su Y, Cheng T, Shi C. 
Newly developed strategies for multifunctional 
mitochondria-targeted agents in cancer therapy. 
Drug Discovery Today. 2011; 16(3-4):140-6.
16. Yamaguchi H. Pathological roles of invadopodia in 
cancer invasion and metastasis. European Journal 
of Cell Biology. 2012; 91(11-12):902-7.
17. Zhang Y, Nolan M, Yamada H, Watanabe M, Nasu 
Y, Takei K, et al. Dynamin2 GTPase contributes to 
invadopodia formation in invasive bladder cancer 
cells. Biochemical and Biophysical Research 
Communications. 2016; 480(3):409-14.
18. Beaty BT, Condeelis J. Digging a little deeper: the 
stages of invadopodium formation and maturation. 
European Journal of Cell Biology. 2014; 93(10-
12):438-44.
19. Gould CM, Courtneidge SA. Regulation of 
invadopodia by the tumor microenvironment. Cell 
Adhesion and Migration. 2014; 8(3):226-35.
20. Yilmaz M, Christofori G. EMT, the cytoskeleton, 
and cancer cell invasion. Cancer and Metastasis 
Reviews. 2009; 28(1-2):15-33.
21. Jacob A, Prekeris R. The regulation of MMP 
targeting to invadopodia during cancer metastasis. 
Frontiers in Cell and Developmental Biology. 
2015; 3:4.
22. Eddy RJ, Weidmann MD, Sharma VP, Condeelis 
JS. Tumor cell invadopodia: invasive protrusions 
that orchestrate metastasis. Trends in Cell Biology. 
2017; 27(8):595-607.
23. Albiges-Rizo C, Destaing O, Fourcade B, Planus E, 
Block MR. Actin machinery and mechanosensitivity 
in invadopodia, podosomes and focal adhesions. 
Journal of Cell Science. 2009; 122(17):3037-49.
24. Weaver AM. Invadopodia: specialized cell 
structures for cancer invasion. Clinical and 
Experimental Metastasis. 2006; 23(2):97-105.
25. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, 
Yamada KM, Mueller SC. Dynamic interactions 
of cortactin and membrane type 1 matrix 
metalloproteinase at invadopodia: defining the 
stages of invadopodia formation and function. 
Cancer Research. 2006; 66(6):3034-43.
26. Meirson T, Gil-Henn H. Targeting invadopodia for 
blocking breast cancer metastasis. Drug Resistance 
Updates. 2018; 39:1-7.
27. Sutoh M, Hashimoto Y, Yoneyama T, Yamamoto 
H, Hatakeyama S, Koie T et al. Invadopodia 
formation by bladder tumor cells. Oncology 
Research Featuring Preclinical and Clinical Cancer 
Therapeutics. 2010; 19(2):85-92.
28. Pourfarhangi KE, Bergman A, Gligorijevic B. ECM 
cross-linking regulates invadopodia dynamics. 
Biophysical Journal. 2018; 114(6):1455-1466
29. Brocato J, Chervona Y, Costa M. Molecular 
responses to hypoxia-inducible factor 1α and 
beyond. Molecular Pharmacology. 2014; 
85(5):651-7.
30. Semenza GL. Hypoxia-inducible factors in 
physiology and medicine. Cell. 2012; 148(3):399-
408.
31. Maher JC, Wangpaichitr M, Savaraj N, Kurtoglu M, 
Lampidis TJ. Hypoxia-inducible factor-1 confers 
resistance to the glycolytic inhibitor 2-deoxy-D-
glucose. Molecular Cancer Therapeutics. 2007; 
6(2):732-41.
32. Nordsmark M, Alsner J, Keller J, Nielsen OS, 
Jensen OM, Horsman MR, Overgaard J. Hypoxia 
in human soft tissue sarcomas: adverse impact on 
survival and no association with p53 mutations. 
British Journal of Cancer. 2001; 84(8):1070.
33. Wang GL, Jiang BH, Rue EA, Semenza GL. 
Hypoxia-inducible factor 1 is a basic-helix-loop-
helix-PAS heterodimer regulated by cellular O2 
tension. Proceedings of the National Academy of 
Sciences. 1995; 92(12):5510-4.
34. Wheaton WW, Chandel NS. Hypoxia. 2. Hypoxia 
regulates cellular metabolism. American Journal of 
Mal J Med Health Sci 15(SP2): 71-80, July 2019 77
Physiology-Cell Physiology. 2010; 300(3):C385-
93.
35. Vaupel P. The role of hypoxia-induced factors in 
tumor progression. The Oncologist. 2004; 910-7.
36. Lu X, Kang Y. Hypoxia and hypoxia-inducible 
factors: master regulators of metastasis. Clinical 
Cancer Research. 2010; 16(24):5928-35.
37. Li JQ, Wu X, Gan L, Yang XL, Miao ZH. Hypoxia 
induces universal but differential drug resistance and 
impairs anticancer mechanisms of 5-fluorouracil 
in hepatoma cells. Acta Pharmacologica Sinica. 
2017; 38(12):1642.
38. Vaupel P, Kelleher DK, Höckel M. Oxygenation 
status of malignant tumors: pathogenesis of hypoxia 
and significance for tumor therapy. In Seminars in 
Oncology 2001; 28(2 Suppl 8):29-35.
39. Bristow RG, Hill RP. Hypoxia and metabolism: 
hypoxia, DNA repair and genetic instability. 
Nature Reviews Cancer. 2008; 8(3):180.
40. Muz B, de la Puente P, Azab F, Azab AK. The role 
of hypoxia in cancer progression, angiogenesis, 
metastasis, and resistance to therapy. Hypoxia. 
2015; 3:83.
41. Brown JM. Exploiting the hypoxic cancer cell: 
mechanisms and therapeutic strategies. Molecular 
Medicine Today. 2000; 6(4):157-62.
42. Yehya AH, Asif M, Tan YJ, Sasidharan S, Majid 
AM, Oon CE. Broad spectrum targeting of tumor 
vasculature by medicinal plants: An updated 
review. Journal of Herbal Medicine. 2017; 9:1-13
43. Xie J, Yang Z, Zhou C, Zhu J, Lee RJ, Teng L. 
Nanotechnology for the delivery of phytochemicals 
in cancer therapy. Biotechnology Advances. 2016; 
34(4):343-53.
44. Liu Q, Loo WT, Sze SC, Tong Y. Curcumin inhibits 
cell proliferation of MDA-MB-231 and BT-483 
breast cancer cells mediated by down-regulation 
of NFκB, cyclinD and MMP-1 transcription. 
Phytomedicine. 2009; 16(10):916-22.
45. Fan Z, Duan X, Cai H, Wang L, Li M, Qu J, et al. 
Curcumin inhibits the invasion of lung cancer cells 
by modulating the PKCα/Nox-2/ROS/ATF-2/MMP-
9 signaling pathway. Oncology Reports. 2015; 
34(2):691-8.
46. Pongrakhananon V, Nimmannit U, Luanpitpong 
S, Rojanasakul Y, Chanvorachote P. Curcumin 
sensitizes non-small cell lung cancer cell anoikis 
through reactive oxygen species-mediated Bcl-2 
downregulation. Apoptosis. 2010; 15(5):574-85.
47. Cao L, Chen X, Xiao X, Ma Q, Li W. Resveratrol 
inhibits hyperglycemia-driven ROS-induced 
invasion and migration of pancreatic cancer cells 
via suppression of the ERK and p38 MAPK signaling 
pathways. International Journal of Oncology. 
2016; 49(2):735-43.
48. Nagaprashantha LD, Vatsyayan R, Singhal J, Lelsani 
P, Prokai L, Awasthi S, et al. 2’-Hydroxyflavanone 
inhibits proliferation, tumor vascularization and 
promotes normal differentiation in VHL-mutant 
renal cell carcinoma. Carcinogenesis. 2011; 
32(4):568-75.
49. Eid EE, Abdul AB, Suliman FE, Sukari MA, Rasedee 
A, Fatah SS. Characterization of the inclusion 
complex of zerumbone with hydroxypropyl-
β-cyclodextrin. Carbohydrate Polymers. 2011; 
83(4):1707-14.
50. Wang S, Su R, Nie S, Sun M, Zhang J, Wu D, et 
al. Application of nanotechnology in improving 
bioavailability and bioactivity of diet-derived 
phytochemicals. The Journal of Nutritional 
Biochemistry. 2014; 25(4):363-76.
51. Salvi A, Thanabalu T. Expression of N-WASP is 
regulated by HIF1α through the hypoxia response 
element in the N-WASP promoter. Biochemistry 
and Biophysics Reports. 2017; 9:13-21.
52. Lee MS, Kim S, Kim BG, Won C, Nam SH, Kang 
S, et al. Snail1 induced in breast cancer cells in 
3D collagen I gel environment suppresses cortactin 
and impairs effective invadopodia formation. 
Biochimica et Biophysica Acta (BBA)-Molecular 
Cell Research. 2014; 1843(9):2037-54.
53. Munoz-Najar UM, Neurath KM, Vumbaca F, 
Claffey KP. Hypoxia stimulates breast carcinoma 
cell invasion through MT1-MMP and MMP-2 
activation. Oncogene. 2006; 25(16):2379.
54. Hamad HA, Kqueen CY, Hashim NF. Invadopodia 
Formation is a Critical Step in Cancer Cell Invasion: 
The Effect of Passage Number on Invadopodia 
Formation in MDA-MB-231 Breast Cancer Cell 
Line. Life Sciences, Medicine and Biomedicine. 
2018 Dec 25;2(3).
55. Harun SN, Israf DA, Tham CL, Lam KW, Cheema 
MS, Md Hashim NF. The Molecular Targets and 
Anti-Invasive Effects of 2, 6-bis-(4-hydroxyl-
3methoxybenzylidine) cyclohexanone or BHMC 
in MDA-MB-231 Human Breast Cancer Cells. 
Molecules. 2018; 23(4):865.
56. Kim JY, Lee JY. Targeting tumor adaption to 
chronic hypoxia: implications for drug resistance, 
and how it can be overcome. International Journal 
of Molecular Sciences. 2017 Sep;18(9):1854.
57. Karakashev SV, Reginato MJ. Progress toward 
overcoming hypoxia-induced resistance to solid 
tumor therapy. Cancer Management and Research. 
2015; 7:253.
58. Jiao M, Nan KJ. Activation of PI3 kinase/Akt/HIF-1α 
pathway contributes to hypoxia-induced epithelial-
mesenchymal transition and chemoresistance in 
hepatocellular carcinoma. International Journal of 
Oncology. 2012; 40(2):461-8.
59. Manolescu B, Oprea E, Busu C, Cercasov C. 
Natural compounds and the hypoxia-inducible 
factor (HIF) signalling pathway. Biochimie. 2009; 
91(11-12):1347-58.
60. Liu R, Liu Y, Zhou YD, Nagle DG. Molecular-
targeted antitumor agents. 15. Neolamellarins from 
the marine sponge Dendrilla nigra inhibit hypoxia-
inducible factor-1 activation and secreted vascular 
Mal J Med Health Sci 15(SP2): 71-80, July 201978
Malaysian Journal of Medicine and Health Sciences (eISSN 2636-9346)
endothelial growth factor production in breast 
tumor cells. Journal of Natural Products. 2007; 
70(11):1741-5.
61. Mirzoeva S, Kim ND, Chiu K, Franzen CA, Bergan 
RC, Pelling JC. Inhibition of HIF‐1 alpha and VEGF 
expression by the chemopreventive bioflavonoid 
apigenin is accompanied by Akt inhibition in 
human prostate carcinoma PC3‐M cells. Molecular 
Carcinogenesis. 2008; 47(9):686-700.
62. He M, Min JW, Kong WL, He XH, Li JX, Peng BW. 
A review on the pharmacological effects of vitexin 
and isovitexin. Fitoterapia. 2016; 115:74-85.
63. Choi HJ, Eun JS, Kim BG, Kim SY, Jeon H, Soh Y. 
Vitexin, an HIF-1α Inhibitor, Has Anti-metastatic 
Potential in PC12 Cells. Molecules and Cells. 
2006; 22(3).
64. Qadir MI, Naqvi ST, Muhammad SA. Curcumin: 
a polyphenol with molecular targets for cancer 
control. Asian Pac J Cancer Prev. 2016;17(6):2735-
9.
65. López‐Lázaro M. Anticancer and carcinogenic 
properties of curcumin: considerations for its 
clinical development as a cancer chemopreventive 
and chemotherapeutic agent. Molecular Nutrition 
& Food Research. 2008 Jun;52(S1):S103-27.
66. Zhong H, De Marzo AM, Laughner E, Lim M, 
Hilton DA, Zagzag D, et al. Overexpression of 
hypoxia-inducible factor 1α in common human 
cancers and their metastases. Cancer Research. 
1999 Nov 15;59(22):5830-5.
67. Duan W, Chang Y, Li R, Xu Q, Lei J, Yin C, 
Li T, Wu Y, Ma Q, Li X. Curcumin inhibits 
hypoxia inducible factor 1α induced epithelial 
mesenchymal transition in HepG2 hepatocellular 
carcinoma cells. Molecular Medicine Reports. 
2014 Nov 1;10(5):2505-10.
68. Cao L, Xiao X, Lei J, Duan W, Ma Q, Li W. 
Curcumin inhibits hypoxia-induced epithelial 
mesenchymal transition in pancreatic cancer cells 
via suppression of the hedgehog signaling pathway. 
Oncology Reports. 2016 Jun 1;35(6):3728-34.
69. Bae MK, Kim SH, Jeong JW, Lee YM, Kim HS, 
Kim SR, Yun I, Bae SK, Kim KW. Curcumin 
inhibits hypoxia-induced angiogenesis via down-
regulation of HIF-1. Oncology Reports. 2006 Jun 
1;15(6):1557-62.
70. Anantharaju PG, Gowda PC, Vimalambike MG, 
Madhunapantula SV. An overview on the role 
of dietary phenolics for the treatment of cancers. 
Nutrition Journal. 2016 Dec;15(1):99.
71. Carocho M, CFR Ferreira I. The role of phenolic 
compounds in the fight against cancer–a review. 
Anti-Cancer Agents in Medicinal Chemistry 
(Formerly Current Medicinal Chemistry-Anti-
Cancer Agents). 2013 Oct 1;13(8):1236-58.
72. Jafari S, Saeidnia S, Abdollahi M. Role of natural 
phenolic compounds in cancer chemoprevention 
via regulation of the cell cycle. Current 
Pharmaceutical Biotechnology. 2014 Apr 
1;15(4):409-21.
73. Jafari S, Saeidnia S, Abdollahi M. Role of natural 
phenolic compounds in cancer chemoprevention 
via regulation of the cell cycle. Current 
Pharmaceutical Biotechnology. 2014 Apr 
1;15(4):409-21.
74. Weng CJ, Yen GC. Chemopreventive effects of 
dietary phytochemicals against cancer invasion 
and metastasis: phenolic acids, monophenol, 
polyphenol, and their derivatives. Cancer 
Treatment Reviews. 2012 Feb 1;38(1):76-87.
75. Yamaguchi H, Lorenz M, Kempiak S, Sarmiento C, 
Coniglio S, Symons M, Segall J, Eddy R, Miki H, 
Takenawa T, Condeelis J. Molecular mechanisms of 
invadopodium formation: the role of the N-WASP–
Arp2/3 complex pathway and cofilin. The Journal 
of Cell Biology. 2005 Jan 31;168(3):441-52.
76. Lin YC, Tsai PH, Lin CY, Cheng CH, Lin TH, Lee 
KP, Huang KY, Chen SH, Hwang JJ, Kandaswami 
CC, Lee MT. Impact of flavonoids on matrix 
metalloproteinase secretion and invadopodia 
formation in highly invasive A431-III cancer cells. 
PloS One. 2013 Aug 21;8(8):e71903.
77. Ansó E, Zuazo A, Irigoyen M, Urdaci MC, 
Rouzaut A, Martínez-Irujo JJ. Flavonoids inhibit 
hypoxia-induced vascular endothelial growth 
factor expression by a HIF-1 independent 
mechanism. Biochemical Pharmacology. 2010 Jun 
1;79(11):1600-9.
78. Franzen CA, Amargo E, Todorović V, Desai BV, 
Huda S, Mirzoeva S, Chiu K, Grzybowski BA, Chew 
TL, Green KJ, Pelling JC. The chemopreventive 
bioflavonoid apigenin inhibits prostate cancer 
cell motility through the focal adhesion kinase/Src 
signaling mechanism. Cancer Prevention Research. 
2009 Sep 1;2(9):830-41.
79. Melstrom LG, Salabat MR, Ding XZ, Strouch MJ, 
Grippo PJ, Mirzoeva S, Pelling JC, Bentrem DJ. 
Apigenin down-regulates the hypoxia response 
genes: HIF-1α, GLUT-1, and VEGF in human 
pancreatic cancer cells. Journal of Surgical 
Research. 2011 May 15;167(2):173-81.
80. Kim WY, Oh SH, Lee HY. Deguelin can sensitize 
the radioresistant cells through blocking HIF-1 and 
angiogenesis. Cancer Research. 2007 May: 751-
75.
81. Zhao H, Jiao Y, Zhang Z. Deguelin inhibits the 
migration and invasion of lung cancer A549 
and H460 cells via regulating actin cytoskeleton 
rearrangement. International Journal of Clinical 
and Experimental Pathology. 2015;8(12):15582.
82. Chen KC, Hsu WH, Ho JY, Lin CW, Chu CY, 
Kandaswami CC, Lee MT, Cheng CH. Flavonoids 
Luteolin and Quercetin Inhibit RPS19 and 
contributes to metastasis of cancer cells through 
c-Myc reduction. Journal of Food and Drug 
Analysis. 2018 Jul 1;26(3):1180-91.
83. Bach A, Bender–Sigel J, Schrenk D, Flügel D, 
Kietzmann T. The antioxidant quercetin inhibits 
Mal J Med Health Sci 15(SP2): 71-80, July 2019 79
cellular proliferation via HIF-1-dependent 
induction of p21WAF. Antioxidants & Redox 
Signaling. 2010 Aug 15;13(4):437-48.
84. Radreau P, Rhodes JD, Mithen RF, Kroon PA, 
Sanderson J. Hypoxia-inducible factor-1 (HIF-1) 
pathway activation by quercetin in human lens 
epithelial cells. Experimental Eye Research. 2009 
Dec 1;89(6):995-1002.
85. Liu WL, Chang JM, Chong IW, Hung YL, Chen 
YH, Huang WT, Kuo HF, Hsieh CC, Liu PL. 
Curcumin inhibits LIN-28A through the activation 
of miRNA-98 in the lung cancer cell line A549. 
Molecules. 2017;22(6):929.
86. Choi H, Chun YS, Kim SW, Kim MS, Park JW. 
Curcumin inhibits hypoxia-inducible factor-1 
by degrading aryl hydrocarbon receptor nuclear 
translocator: a mechanism of tumor growth 
inhibition. Molecular Pharmacology. 2006 Nov 
1;70(5):1664-71.
87. Kizaka‐Kondoh S, Inoue M, Harada H, Hiraoka 
M. Tumor hypoxia: a target for selective cancer 
therapy. Cancer Science. 2003 Dec 1;94(12):1021-
8.
88. Bahrami A, Atkin SL, Majeed M, Sahebkar A. Effects 
of curcumin on hypoxia-inducible factor as a new 
therapeutic target. Pharmacological Research. 
2018 Oct 10: 159-169.
89. Dai J, Fishback JA, Zhou YD, Nagle DG. Sodwanone 
and yardenone triterpenes from a South African 
species of the marine sponge Axinella inhibit 
hypoxia-inducible factor-1 (HIF-1) activation in 
both breast and prostate tumor cells. Journal of 
Natural Products. 2006 Dec 27;69(12):1715-20.
90. Cho H, Lee HY, Ahn DR, Kim SY, Kim S, Lee KB, Lee 
YM, Park H, Yang EG. Baicalein induces functional 
hypoxia-inducible factor-1α and angiogenesis. 
Molecular Pharmacology. 2008 Jul 1;74(1):70-81.
91. Wang L, Ling Y, Chen Y, Li CL, Feng F, You QD, 
Lu N, Guo QL. Flavonoid baicalein suppresses 
adhesion, migration and invasion of MDA-MB-231 
human breast cancer cells. Cancer Letters. 2010 
Nov 1;297(1):42-8.
92. Sung, B., Jhurani, S., Ahn, K.S., Mastuo, Y., Yi, 
T., Guha, S., Liu, M. and Aggarwal, B.B., 2008. 
Zerumbone down-regulates chemokine receptor 
CXCR4 expression leading to inhibition of CXCL12-
induced invasion of breast and pancreatic tumor 
cells. Cancer Research, 68(21), pp.8938-8944.
93. Deep G, Kumar R, Nambiar DK, Jain AK, Ramteke 
AM, Serkova NJ, Agarwal C, Agarwal R. Silibinin 
inhibits hypoxia-induced HIF‐1α‐mediated 
signaling, angiogenesis and lipogenesis in prostate 
cancer cells: In vitro evidence and in vivo 
functional imaging and metabolomics. Molecular 
Carcinogenesis. 2017 Mar;56(3):833-48.
94. Deep G, Kumar R, Jain AK, Agarwal C, Agarwal 
R. Silibinin inhibits fibronectin induced motility, 
invasiveness and survival in human prostate 
carcinoma PC3 cells via targeting integrin 
signaling. Mutation Research/Fundamental and 
Molecular Mechanisms of Mutagenesis. 2014 Oct 
1;768:35-46.
95. Kim YN, Choe SR, Cho KH, Kang J, Park CG, Lee 
HY. Resveratrol suppresses breast cancer cell 
invasion by inactivating a RhoA/YAP signaling 
axis. Experimental & Molecular Medicine. 2018 
Feb;49(2):e296.
96. Weng CJ, Wu CF, Huang HW, Wu CH, Ho CT, Yen 
GC. Evaluation of anti-invasion effect of resveratrol 
and related methoxy analogues on human 
hepatocarcinoma cells. Journal of agricultural and 
food chemistry. 2010 Feb 4;58(5):2886-94.
97. Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, 
Le AD. Resveratrol inhibits hypoxia-induced 
accumulation of hypoxia-inducible factor-1α and 
VEGF expression in human tongue squamous cell 
carcinoma and hepatoma cells. Molecular Cancer 
Therapeutics. 2005 Oct 1;4(10):1465-74.
98. Lu JN, Panchanathan R, Lee WS, Kim HJ, Kim DH, 
Choi YH, Kim G, Shin SC, Hong SC. Anthocyanins 
from the fruit of vitis coignetiae pulliat inhibit tnf-
augmented cancer proliferation, migration, and 
invasion in a549 cells. Asian Pacific Journal of 
Cancer Prevention: APJCP. 2017;18(11):2919.
99. Lu JN, Lee WS, Yun JW, Kim MJ, Kim HJ, Kim DC, 
Jeong JH, Choi YH, Kim GS, Ryu CH, Shin SC. 
Anthocyanins from Vitis coignetiae Pulliat inhibit 
cancer invasion and epithelial-mesenchymal 
transition, but these effects can be attenuated by 
tumor necrosis factor in human uterine cervical 
cancer Hela cells. Evidence-Based Complementary 
and Alternative Medicine. 2013 Jun 20;11.
100. Ziello JE, Jovin IS, Huang Y. Hypoxia-Inducible 
Factor (HIF)-1 regulatory pathway and its potential 
for therapeutic intervention in malignancy 
and ischemia. The Yale Journal of Biology and 
Medicine. 2007 Jun;80(2):51.
101. Gligorijevic B, Wyckoff J, Yamaguchi H, Wang 
Y, Roussos ET, Condeelis J. N-WASP-mediated 
invadopodium formation is involved in intravasation 
and lung metastasis of mammary tumors. Journal of 
Cell Science. 2012 Feb 1;125(3):724-34.
102. Cook MT. Mechanism of metastasis suppression 
by luteolin in breast cancer. Breast Cancer: Targets 
and Therapy. 2018 Oct; 89-100.
103. Yang IH, Shin JA, Lee KE, Kim J, Cho NP, Cho 
SD. Oridonin induces apoptosis in human oral 
cancer cells via phosphorylation of histone H2 
AX. European Journal of Oral Sciences. 2017 
Dec;125(6):438-43.
104. Mu D, Zhou G, Li J, Su B, Guo H. Ursolic acid 
activates the apoptosis of prostate cancer via 
ROCK/PTEN mediated mitochondrial translocation 
of cofilin-1. Oncology letters. 2018 Mar 
1;15(3):3202-6.
105. Wang YS, Lin Y, Li H, Li Y, Song Z, Jin YH. 
The identification of molecular target of (20S) 
ginsenoside Rh2 for its anti-cancer activity. 
Mal J Med Health Sci 15(SP2): 71-80, July 201980
Malaysian Journal of Medicine and Health Sciences (eISSN 2636-9346)
Scientific Reports. 2017 Sep 29;7(1):12408.
106. Song L, Liu D, Zhao Y, He J, Kang H, Dai Z, Wang 
X, Zhang S, Zan Y, Xue X. Sinomenine reduces 
growth and metastasis of breast cancer cells and 
improves the survival of tumor-bearing mice 
through suppressing the SHh pathway. Biomedicine 
& Pharmacotherapy. 2018 Feb 1;98:687-93.
107. Pan Y, Zhang F, Zhao Y, Shao D, Zheng X, 
Chen Y, He K, Li J, Chen L. Berberine enhances 
chemosensitivity and induces apoptosis through 
dose-orchestrated AMPK signaling in breast cancer. 
Journal of Cancer. 2017;8(9):1679-1689.
108. Tian M, Yang S, Yan X. Icariin reduces human 
colon carcinoma cell growth and metastasis by 
enhancing p53 activities. Brazilian Journal of 
Medical and Biological Research. 2018;51(10).
109. Gruhlke M, Nicco C, Batteux F, Slusarenko A. The 
effects of allicin, a reactive sulfur species from 
garlic, on a selection of mammalian cell lines. 
Antioxidants. 2017;6(1):1.
110. Kashyap D, Sharma A, Tuli HS, Sak K, Mukherjee 
T, Bishayee A. Molecular targets of celastrol in 
cancer: Recent trends and advancements. Critical 
Reviews in Oncology/Hematology. 2018 Jun 5.
111. Sikander M, Hafeez BB, Malik S, Alsayari A, 
Halaweish FT, Yallapu MM, Chauhan SC, Jaggi M. 
Cucurbitacin D exhibits potent anti-cancer activity 
in cervical cancer. Scientific Reports. 2016 Nov 
8;6:36594.
